Fonar Header
 
Fonar Press Releases

For Immediate Release

The Inventor of MR Scanning™

An ISO 9001 Company

Contact: Daniel Culver

110 Marcus Drive

Director of Communications

Melville, NY 11747-4292

Web site: www.fonar.com

Phone: (631) 694-2929

Email: investor @ fonar. com

Fax: (631) 390-1709

FONAR REPORTS 12 STRAIGHT QUARTERS OF NET INCOME FROM OPERATIONS AND SIX STRAIGHT QUARTERS OF PROFITABILITY GREATER THAN $ 1.5 MILLION IN 2ND QUARTER FINANCIAL RESULTS

MELVILLE, NEW YORK, February 14, 2013 - FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, reported today its second quarter financial results of fiscal 2013. In addition to profitability being greater than $1.5 million for six straight quarters, the Company has had twelve straight quarters of income from operations. In spite of Hurricane Sandy reaping havoc in the area that four of its scanning centers are located, revenues for FONAR’s imaging management division advanced when compared to a year ago or last quarter. FONAR’s business is based upon utilization of its UPRIGHT® Multi-Position™ MRI, also called the STAND-UP® MRI.

Statement of Operations Items

  • Income from operations for the six months and quarter ended December 31, 2012, was $3.6 million and $1.7 million, respectively, as compared to $3.7 million and $1.9 million respectively, for the same period one year earlier.
  • Net income for the six months and quarter ended December 31, 2012, was $3.4 million and $1.6 million, respectively, as compared to $3.6 million and $1.8 million respectively, for the same period one year earlier.
  • The basic net income per common share available to common stockholders, for the six months and quarter ended December 31, 2012 was $0.44 and $0.21, as compared to $0.50 and $0.25 for the six months and quarter ended December 31, 2011.
  • The diluted net income per common share available to common stockholders, for the six months and quarter ended December 31, 2012 was $0.43 and $0.21, as compared to $0.49 and $0.24 for the six months and quarter ended December 31, 2011.
  • Total revenues for the six months and quarter ended December 31, 2012, was $19.1 million and $9.6 million, respectively, as compared to $18.9 million and $9.3 million for the same period one year earlier.
  • Total operating costs and expenses for the six months and quarter ended December 31, 2012, was $15.5 million and $7.9 million, respectively, as compared to $15.3 million and $7.4 million for the same period one year earlier.
  • Revenue from the management and other fees segment, (HMCA management of the eleven FONAR UPRIGHT® Multi-Position™ MRI diagnostic imaging centers segment), for the six months and quarter ended December 31, 2012, were $11.5 million and $5.7 million respectively, as compared to $9.8 million and $4.9 million for the same period one year earlier. These are increases of 17% and 17% respectively.
  • Revenue from the manufacturing and service segments for the FONAR UPRIGHT® Multi-Position™ MRI for the six months and quarter ended December 31, 2012, was $7.7 million and $3.9 million, respectively, as compared to $9.2 million and $4.4 million for the same period one year earlier.
  • Research & development (R&D) and selling, general & administrative costs (S,G&A), were $2.7 million for the quarter ended December 31, 2012 as compared to $2.3 million for the quarter ended December 31, 2011.

Balance Sheet Items

  • As of December 31, 2012 total current assets were $29.6 million, total assets were $36.8 million, total current liabilities were $21.4 million, and total long-term liabilities were $1.3 million.
  • As of December 31, 2012, total cash and cash equivalents were $14.8 million.
  • As of December 31, 2012, the total stockholder’s equity was $14.1 million.

    See the accompanying tables for more details.

Management Discussion

Raymond V. Damadian, M.D., president and chairman of FONAR said, “I am quite pleased with the Company’s consistent progress since we redefined our corporate business strategy following the 2008 banking crisis. It is remarkable that we have had 1 1/2 years of net income and income from operations exceeding $1.5 million. Each quarter over the past three years we have consistently been profitable having earned income from operations. Our total assets have grown from $21.6 million at June 30, 2010 to $36.8 million most recently, shareholder’s equity has climbed to over $14 million and our long-term liabilities are a low $ 1.25 million.”

“The eleven UPRIGHT® Multi-Position™ MRI centers that we manage continue to add scan volume,” said Dr. Damadian. “In fact, for the three months ended December 31, 2012, the number of scans was 10,563 as compared to 10,332 scans over the same period one year earlier. This occurred in spite of the interruption caused by hurricane Sandy which did cause several of our scanning centers to temporarily stop for a short period.”

“Much of our success comes from the management team assembled that manages the imaging center management business. Key to their success though is the marketing strength of the FONAR STAND-UP® MRI (a.k.a. UPRIGHT® Multi-Position™ MRI). We have a considerable number of customer patients that tell us that they will never go and have a recumbent MRI again. Currently, we are managing eleven centers, all in New York and Florida.

“FONAR's UPRIGHT® MRI technology has opened a new frontier in medical imaging,” said Dr. Damadian. “It is the power to make MRI motion pictures (cinés) of the cerebrospinal fluid (CSF) in the spinal canal as it flows into and out of the brain of the patient while Upright. These ciné MRIs of CSF flow in and out of the brain while the patient is Upright, are uniquely sensitive to the visualization of any impairments of CSF flow. This often leads to a better understanding of the problems with the cervical anatomy that might be contributing to the patient’s symptoms.”

“An example of the severe need of FONAR's unique UPRIGHT® Multi-Position™ MRI technology is FONAR's recent discovery of the potential adverse consequences of cervical spine malalignments. Such cervical spine degenerations or vertebral malalignments can obstruct the flow of cerebrospinal fluid (CSF), which in turn can generate increases of intracranial pressure (ICP) and CSF ‘leakages’ into the surrounding brain parenchyma. It has been proposed that CSF ‘leakages’, such as those shown to be joining the MS lesions in the MRI images of the MS patients studied, could be etiologic in the generation of multiple sclerosis (Damadian R.V., Chu D., ‘The Possible Role of Cranio-Cervical Trauma and Abnormal CSF Hydrodynamics in the Genesis of Multiple Sclerosis’, Physiol. Chem. Phys. & Med. NMR, September 20, 2011, 41:1-17). The report showed that the cervical anatomic abnormalities seen in these MS patients and the resulting CSF flow obstructions were significantly more severe with the patient in the vertical position (Table 2A, col. 10 & 11, Physiol. Chem. Phys. & Med. NMR, September 20, 2011 41:1-17) than with the patient in the recumbent position. Consequently, it is critical that any assessment of CSF flow impairment in the brain or spinal column must be assessed with the patient in the vertical position in order to determine the full extent of the CSF flow impairment, the extent of treatment needed and, most importantly, to achieve an accurate assessment post-treatment of the degree to which satisfactory CSF flow has been successfully restored. Accordingly,” said Dr. Damadian, “we believe there now exists a genuine hope that if an MS patient can have their vertical position CSF flow and intracranial pressures (ICP) monitored and restored to normal, then there is also the prospect that the symptoms of this MS patient can be restored to normal.”

About FONAR

FONAR (NASDAQ:FONR), Melville, NY, The Inventor of MR Scanning™, is an AMERICAN COMPANY that was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world’s first commercial MRI in 1980, and went public in 1981. Since its inception, nearly 300 recumbent-OPEN MRIs and over 150 UPRIGHT® Multi-Position™ MRI scanners have been installed worldwide. FONAR’s stellar product is the UPRIGHT® MRI (also known as the STAND-UP® MRI), the only whole-body MRI that performs Position™ imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often sees the patient’s problem that other scanners cannot because they are lie-down only. The patient-friendly UPRIGHT® MRI has a near-zero claustrophobic rejection rate by patients. As a FONAR customer states, “If the patient is claustrophobic in this scanner, they’ll be claustrophobic in my parking lot.” Approximately 85% of patients are scanned sitting while they watch a 42” flat screen TV. FONAR is headquartered on Long Island, New York.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, Multi-Position™, Upright Radiology™, The Proof is in the Picture™, True Flow™, pMRI™, Spondylography™, Dynamic™, Spondylometry™, CSP™, and Landscape™, are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.

CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)

ASSETS

 
December 31,
2012
(UNAUDITED) 
June 30,
2012
   
Current Assets:
   
Cash and cash equivalents      
$ 14,760
$ 12,032
Accounts receivable - net
4,920
5,095
Accounts receivable - related party
60
-
Management and other fees receivable - net
4,525
3,782
Management and other fees receivable - related medical practices - net
1,955
1,311
Costs and estimated earnings in excess of billings on uncompleted contracts
747
1,129
Inventories
2,239
2,195
Current portion of notes receivable - net
118
116
Prepaid expenses and other current assets
251
206
Total Current Assets

29,575

25,866

Property and Equipment - net
2,927

3,173

Notes Receivable

207
276
Other Intangible Assets – Net
3,609
3,835
Other Assets
487
465
Total Assets
$ 36,805
================
$ 33,615
================

CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED, except per share data)

LIABILITIES AND STOCKHOLDERS’ EQUITY


December 31,
2012
(UNAUDITED) 

June 30,
2012
 

Current Liabilities:
Current portion of long-term debt and capital leases
$ 1,483
1,854
Accounts payable
2,020
2,077
Other current liabilities
8,179
7,693
Unearned revenue on service contracts
5,536
5,475
Unearned revenue on service contracts - related party
55
-
Customer advances
4,138
3,881
Income tax payable
-
100
Total Current Liabilities
21,411
21,080
 
Long-Term Liabilities:
Accounts payable – non current
10
47
Due to related medical practices
229
229
Long-term debt and capital leases, less current portion
634
777
Other liabilities
379
401
Total Long-Term Liabilities
1,252
1,454
Total Liabilities
22,663
22,534

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(000’s OMITTED, except per share data)

LIABILITIES AND STOCKHOLDERS’ EQUITY(Continued)

     
 
December 31,
2012
(UNAUDITED)
 June 30,
2012
 
STOCKHOLDERS' EQUITY:
   
Class A non-voting preferred stock $.0001 par value; 453,000 shares authorized at December 31, 2012 and June 30, 2012, 313,438 issued and outstanding at December 31, 2012 and June 30, 2012
-
-
Preferred stock $.001 par value; 567,000 shares authorized at December 31, 2012 and June 30, 2012, issued and outstanding – none
-
-
Common Stock $.0001 par value; 8,500,000 shares authorized at December 31, 2012 and June 30, 2012, 5,942,905 and 5,912,905 issued at December 31, 2012 and June 30, 2012, respectively; 5,931,262 and 5,901,262 outstanding at December 31, 2012 and June 30, 2012, respectively
1
1
Class B Common Stock (10 votes per share) $ .0001 par value; 227,000 shares authorized at December 31, 2012 and June 30, 2012, 158 issued and outstanding at December 31, 2012 and June 30, 2012
-
-
Class C Common Stock (25 votes per share) $.0001 par value; 567,000 shares authorized at December 31, 2012 and June 30, 2012, 382,513 issued and outstanding at December 31, 2012 and June 30, 2012
-
-
Paid-in capital in excess of par value
174,231
174,084
Accumulated other comprehensive loss
(20)
(20)
Accumulated deficit
(165,533)
(168,334)
Notes receivable from employee stockholders
(59)
(71)
Treasury stock, at cost - 11,643 shares of common stock at December 31, 2012 and June 30, 2012
(675)

(675)
Non controlling interests
6,197
6,096
Total Stockholders' Equity
14,142
11,081
Total Liabilities and Stockholders' Equity
$ 36,805
================
$ 33,615
================

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(000'S OMITTED, except per share data

 
FOR THE THREE MONTHS ENDED
DECEMBER 31,
REVENUES
2012    
2011    
Product sales - net
$ 1,080
$ 1,615
Service and repair fees - net
2,765
2,807
Service and repair fees - related parties - net
28
27
Management and other fees - net
3,775
3,308
Management and other fees–related medical practices – net
1,965
1,571
Total Revenues - Net
9,613
9,328
COSTS AND EXPENSES
Costs related to product sales
904
1,171
Costs related to service and repair fees
894
868
Costs related to service and repair fees - related parties
9
9
Costs related to management and other fees
2,235
1,887
Costs related to management and other fees - related medical practices
852
901
Research and development
320
293
Selling, general and administrative
2,352
1,995
Provision for bad debts
325
310
Total Costs and Expenses
7,891
7,434
Income From Operations
1,722
1,894
Interest Expense
(103)
(124)
Investment Income
60
64
Other Income
(4)
(1)

Income Before Provision for Income Taxes and Non Controlling Interests

1,675
1,833

Provision for Income Taxes

55
21

Net Income

1,620
1,812

Net Income - Non Controlling Interests

271

276

Net Income - Controlling Interests
$ 1,349
================
$ 1,536
================
Net Income Available to Common Stockholders
$ 1,259
================
$ 1,432
================
Net Income Available to Class A Non-Voting Preferred Stockholders
$ 67
================
$ 78
================
Net Income Available to Class C Common Stockholders
$ 23
================
$ 26
================
Basic Net Income Per Common Share Available to Common Stockholders
$ 0.21
================
$ 0.25
================
Diluted Net Income Per Common Share Available to Common Stockholders
$ 0.21
================
$ 0.24
================
Basic and Diluted Income Per Share - Common C
$ 0.06
================
$ 0.07
================

Weighted Average Basic Shares Outstanding

5,926,262
================
5,728,528
================

Weighted Average Diluted Shares Outstanding

6,053,766
================
5,856,032
================
Weighted Average Basic Shares Outstanding – Class C Common
382,513
================
382,513
================
Weighted Average Diluted Shares Outstanding – Class C Common
382,513
================
382,513
================

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(000'S OMITTED, except per share data

 
FOR THE SIX MONTHS ENDED
DECEMBER 31,
REVENUES
2012    
2011    
Product sales - net
$ 2,121
$ 3,391
Service and repair fees - net
5,474
5,712
Service and repair fees - related parties - net
55
55
Management and other fees - net
7,544
6,637
Management and other fees–related medical practices – net
3,930
3,141
Total Revenues - Net
19,124
18,936
COSTS AND EXPENSES
Costs related to product sales
1,959
2,646
Costs related to service and repair fees
1,760
1,682
Costs related to service and repair fees - related parties
18
16
Costs related to management and other fees
4,406
4,072
Costs related to management and other fees - related medical practices
1,669
1,720
Research and development
650
622
Selling, general and administrative
4,564
4,037
Provision for bad debts
500
485
Total Costs and Expenses
15,526
15,280
Income From Operations
3,598
3,656
Interest Expense
(179)
(231)
Investment Income
120
126
Other (Expense) Income
(13)
55

Income Before Provision for Income Taxes and Non Controlling Interests

3,526
3,606

Provision for Income Taxes

127
21

Net Income

3,399
3,585

Net Income - Non Controlling Interests

598

535

Net Income - Controlling Interests
$ 2,801
================
$ 3,050
================
Net Income Available to Common Stockholders
$ 2,616
================
$ 2,842
================
Net Income Available to Class A Non-Voting Preferred Stockholders
$ 138
================
$ 155
================
Net Income Available to Class C Common Stockholders
$ 47
================
$ 53
================
Basic Net Income Per Common Share Available to Common Stockholders
$ 0.44
================
$ 0.50
================
Diluted Net Income Per Common Share Available to Common Stockholders
$ 0.43
================
$ 0.49
================
Basic and Diluted Income Per Share - Common C
$ 0.12
================
$ 0.14
================

Weighted Average Basic Shares Outstanding

5,913,762
================
5,698,645
================

Weighted Average Diluted Shares Outstanding

6,041,266
================
5,826,149
================
Weighted Average Basic Shares Outstanding – Class C Common
382,513
================
382,513
================
Weighted Average Diluted Shares Outstanding – Class C Common
382,513
================
382,513
================

 

FONAR™ Corporation
110 Marcus Drive
Melville, N.Y. 11747
Tel. 631-694-2929
Fax. 631-390-9540
Email sales@FONAR.com
Investor Information

top of page

Site Map | Terms of Use-Our Privacy Policy Use
Copyright 2013 FONAR- All Rights Reserved